ES2320743T3 - Mutantes de quimiocina que actuan como antagonistas de quimiocinas. - Google Patents

Mutantes de quimiocina que actuan como antagonistas de quimiocinas. Download PDF

Info

Publication number
ES2320743T3
ES2320743T3 ES02791832T ES02791832T ES2320743T3 ES 2320743 T3 ES2320743 T3 ES 2320743T3 ES 02791832 T ES02791832 T ES 02791832T ES 02791832 T ES02791832 T ES 02791832T ES 2320743 T3 ES2320743 T3 ES 2320743T3
Authority
ES
Spain
Prior art keywords
baselineskip
chemokine
rantes
mutants
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02791832T
Other languages
English (en)
Spanish (es)
Inventor
Amanda Proudfoot
Marie Kosco-Vilbois
Jeffrey Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of ES2320743T3 publication Critical patent/ES2320743T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES02791832T 2001-12-17 2002-12-16 Mutantes de quimiocina que actuan como antagonistas de quimiocinas. Expired - Lifetime ES2320743T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000761 2001-12-17
EP01000761 2001-12-17

Publications (1)

Publication Number Publication Date
ES2320743T3 true ES2320743T3 (es) 2009-05-28

Family

ID=8176112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02791832T Expired - Lifetime ES2320743T3 (es) 2001-12-17 2002-12-16 Mutantes de quimiocina que actuan como antagonistas de quimiocinas.

Country Status (10)

Country Link
US (1) US7553483B2 (https=)
EP (1) EP1458756B1 (https=)
JP (1) JP2005525089A (https=)
AT (1) ATE421974T1 (https=)
AU (1) AU2002358144B2 (https=)
CA (1) CA2468790A1 (https=)
DE (1) DE60231057D1 (https=)
ES (1) ES2320743T3 (https=)
IL (1) IL162600A0 (https=)
WO (1) WO2003051921A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE394117T1 (de) 2002-12-23 2008-05-15 Serono Lab Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
WO2010071610A1 (en) * 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2380975A1 (de) * 2010-04-22 2011-10-26 Scil Proteins GmbH Verfahren zur Herstellung von rekombinantem Thrombin
US9717777B2 (en) 2010-05-05 2017-08-01 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US9352000B2 (en) * 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
US10967015B2 (en) * 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017077062A1 (en) * 2015-11-05 2017-05-11 Ludwig-Maximilians-Universität München A peptide derived from human neutrophile peptide 1
KR102682118B1 (ko) 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
WO2023057589A1 (en) 2021-10-06 2023-04-13 Virothera Ltd Novel immune regulator

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057123A (en) 1991-12-23 2000-05-02 British Biotech Pharmaceuticals Limited Stem cell inhibiting proteins
FI972433A0 (fi) * 1994-12-08 1997-06-06 Glaxo Group Ltd Rantes-peptidi ja fragmentteja sekä tätä sisältäviä tulehduksen hoitoon soveltuvia koostumuksia
WO1998024908A1 (en) 1996-12-05 1998-06-11 Human Genome Sciences, Inc. Human chemokine beta-13
AU5137698A (en) 1996-12-05 1998-06-29 Kyowa Hakko Kogyo Co. Ltd. Novel dna, novel protein, and novel antibody
EP0906954A1 (en) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
ATE308617T1 (de) 1997-12-23 2005-11-15 San Raffaele Centro Fond Rantes mutanten und deren therapeutischen anwendungen
JPH11243960A (ja) * 1998-03-06 1999-09-14 Shionogi & Co Ltd ヒトcc型ケモカインエオタキシン3
DE69910216T2 (de) * 1998-07-22 2004-02-19 Osprey Pharmaceuticals Ltd., Calgary Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis

Also Published As

Publication number Publication date
AU2002358144A1 (en) 2003-06-30
ATE421974T1 (de) 2009-02-15
US7553483B2 (en) 2009-06-30
WO2003051921A1 (en) 2003-06-26
IL162600A0 (en) 2005-11-20
CA2468790A1 (en) 2003-06-26
AU2002358144B2 (en) 2008-10-02
JP2005525089A (ja) 2005-08-25
EP1458756A1 (en) 2004-09-22
US20050220757A1 (en) 2005-10-06
EP1458756B1 (en) 2009-01-28
DE60231057D1 (de) 2009-03-19

Similar Documents

Publication Publication Date Title
ES2320743T3 (es) Mutantes de quimiocina que actuan como antagonistas de quimiocinas.
ES2282666T3 (es) Antagonistas de quimiocinas cxc de union a cxcr3.
US7425324B2 (en) Antagonists of MCP proteins
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
PL204231B1 (pl) Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza
US6709649B1 (en) RANTES derived peptides with anti-HIV activity
JP2011501675A (ja) Sdf−1を基礎としたグリコサミノグリカンアンタゴニスト、及びその使用方法
ES2254938T3 (es) Mutantes de quimioquinas que poseen biodisponibilidad oral mejorada.
EP1673388B1 (en) Cxcl8 antagonists
US20080299072A1 (en) Chemokine Antagonists
WO2008015199A1 (en) Chemokine antagonists
WO2005056581A2 (en) Peptide able to specifically bind a chemokine receptor and use thereof